Peripheral antigen presentation by lymph node stromal cell

Peripheral antigen presentation by lymph node stromal cells refers to the ability of nonhematopoietic stromal cells within the lymph nodes—such as fibroblastic reticular cells, lymphatic endothelial cells, and blood endothelial cells—to present antigens to T cells. These stromal populations were once thought to be purely structural but are now recognized as active participants in immune regulation. They can express both MHC class I and II molecules, allowing them to present self-antigens or exogenous antigens with tolerogenic consequences for both CD8+ and CD4+ T cells. This mechanism helps maintain peripheral tolerance by deleting autoreactive T cells or inducing regulatory T cell development, thus preventing autoimmunity while also shaping adaptive immune responses during infection or cancer. However, "peripheral antigen presentation by lymph node stromal cell" describes a biological process involving multiple cellular players rather than a specific therapeutic target such as an individual receptor or enzyme[1][5][7]. **Note:** This entry does **not** correspond to an individual molecule/receptor/protein but instead describes an immunological function performed collectively by several types of nonhematopoietic stromal cells in the lymph node microenvironment. Therefore, it should not be considered a canonical therapeutic target according to standard definitions used for drug discovery purposes.

Other names

Antigen presentation by lymph node stromal cellLNSC-mediated antigen presentationStromal cell antigen presentation in lymph node

null (no drugs directly target this process; it is a cellular function rather than a discrete druggable molecule)